ライフサイエンスコーパス: CTO

1 CTO PCI was successful in 10,199 cases (70.6%).

2 ated with drug-eluting stents for at least 1 CTO (>3 months).

3 to 3.83 years), successful PCI of at least 1 CTO was associated with improved survival (hazard ratio

4 At least 1 CTO was present in 71 (44%) patients.

5 1,035 patients underwent PCI for at least 1 CTO.

6 The Collagenase Total Occlusion-1 (CTO-1) Trial is a phase I, dose-escalation trial to asse

7 METHODS AND We analyzed 1253 CTO percutaneous coronary intervention procedures perfor

8 ers of patients readmitted (100 [61%] of 165 CTOs vs 113 [68%] of 165 controls; relative risk 0.88 [9

9 nts disengaged from services (12 [7%] of 165 CTOs vs 7 [4%] of 165 controls).

10 A total of 1,253 CTO-PCIs were performed in 1,177 patients, of which 86%

11 mean age of 63.5 years and underwent 14,439 CTO procedures.

12 atient and procedural characteristics of 470 CTO cases treated from January 2010 to December 2015 dep

13 ere collected from 1,395 patients with 1,582 CTO lesions enrolled between January 2008 and December 2

14 A total of 376 CP were recorded from 26 807 CTO-PCI interventions (incidence of 1.40%) with an incre

15 s the half of all operators who performed <9 CTO PCIs per year.

16 patients (1:1) to be discharged on either a CTO (n=167) or to voluntary status via Section 17 leave

17 Mayo Clinic registry who required PCI for a CTO.

18 007 consecutive patients underwent PCI for a CTO.

19 rted series of patients undergoing PCI for a CTO.

20 rvival for patients with successful PCI of a CTO has not been clearly defined.

21 Percutaneous coronary intervention of a CTO is a common occurrence, and the long-term survival f

22 ort to determine whether successful PCI of a CTO is associated with improved survival.

23 Recanalization of a CTO results in a modest increase in the FFR of the predo

24 oing percutaneous coronary intervention of a CTO, coronary pressure and flow velocity were measured a

25 with successful versus unsuccessful PCI to a CTO.

26 Additional CTO PCI within 1 week after primary PCI for STEMI was fe

27 ether the recovery of anterograde flow after CTO recanalization with drug-eluting stent implantation

28 pnea reported less dyspnea improvement after CTO PCI.

29 TOs) and predictors of its improvement after CTO percutaneous coronary intervention (PCI) are unknown

30 , 70% reported less dyspnea at 1 month after CTO PCI.

31 Dyspnea Scale at baseline and 1 month after CTO PCI.

32 is severe impairment of vasomotor tone after CTO reopening suggests that intracoronary ultrasound ass

33 (p < 0.001) or media (p = 0.0001) across all CTO ages.

34 Central Cardiac Audit Database for all CTO PCI cases carried out in England and Wales between J

35 ascular Intervention Society data set on all CTO-PCI procedures performed in England and Wales betwee

36 had complete revascularization (CR) for all CTOs and other diseased lesions.

37 ention was done in 30% of patients, although CTO lesions were attempted in only 10% (with 70% success

38 e analyzed patients with concomitant ULM and CTO-RCA, cardiac-death was significantly higher in patie

39 ous coronary intervention for stable angina (CTO-PCI) is a rare but serious event.

40 Angiographic CTO frequently corresponds to less than complete occlusi

41 Ninety-six angiographic CTOs from autopsy studies in 61 patients who had undergo

42 Operators with annual CTO PCI volumes of at least 48 per year (the top volume

43 Carotid artery CTO was created by balloon injury in 19 lipid-overfed sw

44 otal occlusion of the right coronary artery (CTO-RCA) in patients undergoing percutaneous interventio

45 interventions and with or without associated CTO-RCA.

46 Post-CABG CTO PCI is associated with similar high success and low

47 Procedural factors indicative of complex CTO intervention strongly related to an increased risk o

48 neous coronary intervention of a concomitant CTO.

49 d whether patients with STEMI and concurrent CTO in a non-infarct-related artery benefit from additio

50 In patients with STEMI and concurrent CTO, we did not find an overall benefit for CTO PCI in t

51 who underwent primary PCI and had concurrent CTO in 14 centers in Europe and Canada.

52 One hundred consecutive CTOs successfully treated with drug-eluting stents under

53 etrograde PCI revascularization for coronary CTOs.

54 cisions regarding patients who have coronary CTOs identified during coronary angiography.

55 e randomly assigned to early PCI of the CTO (CTO PCI), and 154 patients were assigned to conservative

56 Real-time MRI intervention used custom CTO catheters and guidewires that incorporated MRI recei

57 ntly between the two groups (median 183 days CTO group vs 8 days Section 17 group, p<0.001) the numbe

58 are required to more definitively determine CTO revascularization guidelines.

59 Appropriate use criteria ratings downgrade CTO percutaneous coronary intervention revascularization

60 dence, predictors, and outcomes of CP during CTO-PCI were defined.

61 The finding that early CTO PCI in the left anterior descending coronary artery

62 uccessful CTO treatment compared with failed CTO treatment (73.5% vs. 65.1%, p = 0.001).

63 The Florence CTO PCI registry started in 2003 and included consecutiv

64 n registry adopting the hybrid algorithm for CTO percutaneous coronary intervention (Registry of Cros

65 CTO, we did not find an overall benefit for CTO PCI in terms of LVEF or LVEDV.

66 Percutaneous coronary intervention for CTO remains a challenge with a high incidence of procedu

67 The success rate for CTO is low compared with the rate for other lesions.

68 Procedural success rates for CTO have not improved over time in the stent era, highli

69 its improvement among patients selected for CTO PCI.

70 agnosis of psychosis and deemed suitable for CTOs by their clinicians.

71 fTRA CTO percutaneous coronary intervention is a valid altern

72 histology, 3 underwent primary x-ray-guided CTO recanalization attempts, and the remaining 14 underw

73 pothesized that real-time MRI (rtMRI)-guided CTO recanalization can be accomplished in an animal mode

74 The rtMRI-guided CTO recanalization was successful in 11 of 14 swine and

75 atory and calibration capacity for guidewire CTO crossing within 30 minutes but it does not for final

76 2015, consecutive patients undergoing hybrid CTO-PCI were prospectively enrolled in 17 centers.

77 vascularization on quality of life, risks in CTO revascularization, and the importance of complete re

78 n this study, supporting its expanded use in CTO interventions.

79 In CTOs >1 year old, the adventitia and IP NC numbers were

80 In CTOs < 1 year old, the adventitia was associated with a

81 J-CTO score was strongly associated with final success and

82 R: 2.43; 95% CI: 1.22 to 4.83; p = 0.011), J-CTO (Multicenter CTO Registry in Japan) score >/=3 (HR:

83 , difficult (J-CTO=2), and very difficult (J-CTO>/=3).

84 CTO=0), intermediate (J-CTO=1), difficult (J-CTO=2), and very difficult (J-CTO>/=3).

85 fty-seven lesions were classified as easy (J-CTO=0), intermediate (J-CTO=1), difficult (J-CTO=2), and

86 ost-CABG patients (175 cases) had a higher J-CTO score (2.5 versus 2.1; P=0.002).

87 lassified as easy (J-CTO=0), intermediate (J-CTO=1), difficult (J-CTO=2), and very difficult (J-CTO>/

88 The mean J-CTO score was 2.18+/-1.26, and successful guidewire cros

89 ance of the Japan-chronic total occlusion (J-CTO) score in predicting success and efficiency of CTO p

90 verall mean Japan-Chronic Total Occlusion (J-CTO) score was 1.43+/-1.16, with no differences between

91 minutes for every 1-point increase of the J-CTO score (regression coefficient 22.33, 95% confidence

92 The J-CTO score demonstrated good discrimination (c statistic,

93 We investigated the performance of the J-CTO score for predicting procedure complexity and succes

94 The J-CTO score has been proposed to stratify case complexity

95 The J-CTO score helps to predict complexity of CTO recanalizat

96 The impact of the J-CTO score on technical success and procedure time was ev

97 In this independent cohort, the J-CTO score showed good discriminatory and calibration cap

98 The J-CTO score was applied for each patient, and discriminati

99 The J-CTO score was associated with a 2-fold increase in the o

100 l success rate was not associated with the J-CTO score.

101 The average Japanese CTO score was 2.0 +/- 1.0, and was higher in the failure

102 The average Japanese CTO score was 2.1+/-1.2 in fTRA and 2.3+/-1.1 in TFA (P=

103 rable for fTRA and TFA in different Japanese CTO score subgroups after multivariable analysis and aft

104 Recanalization of long CTO is entirely feasible with the use of rtMRI guidance.

105 1.22 to 4.83; p = 0.011), J-CTO (Multicenter CTO Registry in Japan) score >/=3 (HR: 2.08; 95% CI: 1.3

106 rvative treatment without PCI of the CTO (no CTO PCI).

107 O PCI arm versus 212.8 +/- 60.3 ml in the no-CTO PCI arm (p = 0.70).

108 compared with patients randomized to the no-CTO PCI strategy (47.2 +/- 12.3% vs. 40.4 +/- 11.9%; p =

109 The 10-year survival rates for matched non-CTO and the CTO cohorts were similar.

110 ng propensity scoring methods, a matched non-CTO cohort of 2,007 patients was identified and compared

111 ry artery occlusion (CTO) with a matched non-CTO cohort to determine whether successful PCI of a CTO

112 The CTO versus non-CTO 10-year survival was the same (71.2% vs. 71.4%, p =

113 tervention revascularization relative to non-CTOs and to surgical revascularization.

114 III or IV angina caused by nonrecanalizable CTOs, the performance of PTMR does not result in a great

115 f a chronic total coronary artery occlusion (CTO) with a matched non-CTO cohort to determine whether

116 oncomitant chronic total coronary occlusion (CTO) and a large collateral contribution might alter the

117 sease have chronic total coronary occlusion (CTO), which is associated with long-term mortality in pa

118 with single-vessel chronic total occlusion (CTO) and no prior myocardial infarction (MI).

119 f peripheral artery chronic total occlusion (CTO) can be challenging.

120 re after successful chronic total occlusion (CTO) drug-eluting stent-supported percutaneous coronary

121 concurrent coronary chronic total occlusion (CTO) in a non-infarct-related artery is present and is a

122 Chronic total occlusion (CTO) is common, being reported in 18% to 30% of patients

123 ybrid algorithm for chronic total occlusion (CTO) percutaneous coronary intervention (PCI) was develo

124 radial approach for chronic total occlusion (CTO) percutaneous coronary intervention.

125 Chronic total occlusion (CTO) recanalization is a complex and technically challen

126 evascularization of chronic total occlusion (CTO).

127 rvention (PCI) for chronic total occlusions (CTO) has been identified as a beneficial treatment, but

128 rvention (PCI) for chronic total occlusions (CTO) over the last 25 years from a single PCI registry a

129 rvention (PCI) for chronic total occlusions (CTO).

130 ic chronic total coronary artery occlusions (CTOs) were studied to define histologic correlates of ag

131 of native coronary chronic total occlusions (CTOs) after coronary artery bypass grafts (CABGs) is hig

132 e in patients with chronic total occlusions (CTOs) and predictors of its improvement after CTO percut

133 gement of coronary chronic total occlusions (CTOs) in current practice.

134 sed by one or more chronic total occlusions (CTOs) of a native coronary artery.

135 ms reveal coronary chronic total occlusions (CTOs).

136 entions (PCIs) for chronic total occlusions (CTOs).

137 and could partly account for the absence of CTO effect.

138 Specific aspects of CTO revascularization include ischemic burden, impact of

139 th hard clinical outcomes on the benefits of CTO revascularization has hampered attempts to develop r

140 e J-CTO score helps to predict complexity of CTO recanalization, and the simplicity of the score supp

141 st studies have used variable definitions of CTO, and there are limited data available from contempor

142 We also tested whether duration of CTO affected readmission outcomes in patients with CTO e

143 between readmission outcomes and duration of CTO.

144 core in predicting success and efficiency of CTO percutaneous coronary intervention has received limi

145 mong other characteristics, the existence of CTO was assessed.

146 However, the impact of CTO on the occurrence of ventricular arrhythmias and lon

147 s much higher than expected, irrespective of CTO status, and could partly account for the absence of

148 We examined outcomes of CTO percutaneous coronary intervention (PCI) post-CABG v

149 percutaneous coronary intervention (PCI) of CTO shortly after primary PCI.

150 The presence of CTO was associated with higher ventricular arrhythmia an

151 who underwent unsuccessful PCI procedures of CTO (more than three months' duration) had a repeat atte

152 Recanalization of CTO is followed by a hibernation of vascular wall at dis

153 hese findings suggest that recanalization of CTO-RCA has significant impact on the long-term cardiac-

154 Successful revascularization of CTO is associated with improved survival compared with p

155 cilitating percutaneous revascularization of CTO.

156 , we looked at the feasibility and safety of CTO PCI via saphenous vein grafts (19% of post-CABG case

157 The percutaneous treatment of CTO remains a major challenge.

158 mine the utilization and variation in use of CTO PCI, the success rates across providers, the multiva

159 We previously investigated the effect of CTOs on readmission rates over 12 months in a randomised

160 nal trial to examine the long-term effect of CTOs on readmissions and the risk of patients disengagin

161 ndations regarding the optimal management of CTOs.

162 Revascularization of CTOs is frequently characterized by inability to cross o

163 e adverse revascularization profile of older CTOs.

164 ned to be discharged from hospital either on CTO (167 patients) or Section 17 leave (169 patients).

165 io) to be discharged from hospital either on CTO or Section 17 leave.

166 sis of psychosis discharged from hospital on CTOs would have a lower rate of readmission over 12 mont

167 METHODS AND In the OPEN CTO registry (Outcomes, Patient health status, and Effic

168 Community treatment orders (CTOs) for psychiatric patients became available in Engla

169 Community treatment orders (CTOs) have not been shown in randomised trials to reduce

170 y observed in patients with ULM and residual CTO-RCA as compared with those without residual CTO-RCA

171 eated CTO-RCA), and 46 patients had residual CTO-RCA.

172 ed less frequently in patients with residual CTO-RCA (adjusted hazard ratios, 0.321 [95% confidence i

173 ed more frequently in patients with residual CTO-RCA as compared with those without residual CTO-RCA.

174 these, 522 had ULM lesions without residual CTO-RCA (493 ULM without CTO-RCA+29 ULM with treated CTO

175 -RCA as compared with those without residual CTO-RCA (adjusted hazard ratios, 2.163 [95% confidence i

176 -RCA as compared with those without residual CTO-RCA.

177 X-ray angiography resolves CTO poorly.

178 anuary 2008 and December 2012 for retrograde CTO PCI at 44 European centers.

179 ed at feasibility and outcomes of retrograde CTO PCI via patent or occluded saphenous vein graft.

180 A successfully revascularized CTO confers a significant 10-year survival advantage com

181 eceiving ICDs for primary prevention of SCD, CTO is an independent predictor for the occurrence of ve

182 Successful CTO PCI was associated with improved long-term survival.

183 Successful CTO PCI was associated with more frequent dyspnea improv

184 Successful CTO-PCI supported by everolimus-eluting stents is associ

185 tion, or reocclusion 1 year after successful CTO PCI in patients treated before February 2015.

186 ut the angiographic outcome after successful CTO PCI.

187 ct 10-year survival advantage for successful CTO treatment compared with failed CTO treatment (73.5%

188 of success, and the mortality of successful CTO PCI.

189 survival benefit in patients with successful CTO PCI.

190 Patients with successful CTO PCIs were younger; had higher ejection fractions; we

191 Contemporary data suggest CTO revascularization may have substantial impact on pat

192 erwent coronary artery bypass graft surgery (CTO bypassed in 88%).

193 This review presents issues surrounding CTO revascularization within the framework of the approp

194 Multivariable analysis revealed that CTO was independently associated with appropriate ICD in

195 follow-up support our original findings that CTOs do not provide patient benefits, and the continued

196 The CTO experience group had significantly more readmissions

197 The CTO versus non-CTO 10-year survival was the same (71.2%

198 r survival rates for matched non-CTO and the CTO cohorts were similar.

199 noted no significant difference between the CTO and control groups for time to disengagement or numb

200 ar disease; and were more likely to have the CTO in the left anterior descending artery.

201 Diabetics in the CTO cohort had a lower 10-year survival compared with no

202 se cardiac event (MACE) rate was 3.8% in the CTO cohort.

203 g a total sample of 333 patients (166 in the CTO group and 167 in the Section 17 group).

204 ween groups (59 [36%] of 166 patients in the CTO group vs 60 [36%] of 167 patients in the Section 17

205 ator-reported procedural success rate in the CTO PCI arm of the trial was 77%, and the adjudicated su

206 EDV at 4 months was 215.6 +/- 62.5 ml in the CTO PCI arm versus 212.8 +/- 60.3 ml in the no-CTO PCI a

207 s were randomly assigned to early PCI of the CTO (CTO PCI), and 154 patients were assigned to conserv

208 to conservative treatment without PCI of the CTO (no CTO PCI).

209 unreliable at predicting ischemia should the CTO vessel be revascularized and potentially affecting t

210 hic evidence of Q waves corresponding to the CTO artery territory in only 26% of cases.

211 patients was identified and compared to the CTO group.

212 g coronary artery who were randomized to the CTO PCI strategy had significantly higher LVEF compared

213 Technical failure to treat the CTO was not an independent predictor of long-term mortal

214 Half the CTOs were located in the right coronary artery.

215 ation of readmission in patients assigned to CTO versus those assigned to control, and in all patient

216 with an increased risk of CP were related to CTO complexity.

217 r a broad community of appropriately trained CTO operators.

218 ients with residual as compared with treated CTO-RCA (log-rank P=0.01) despite no difference in basel

219 (493 ULM without CTO-RCA+29 ULM with treated CTO-RCA), and 46 patients had residual CTO-RCA.

220 experienced centers, 987 patients undergoing CTO PCI (procedure success 82%) were assessed for dyspne

221 s a common symptom among patients undergoing CTO PCI and improves significantly with successful PCI.

222 030 (3.1%) patients undergoing PCI underwent CTO PCI with a success rate of 61.3%.

223 ds of 650 consecutive patients who underwent CTO percutaneous coronary intervention between 2011 and

224 al of 209 consecutive patients who underwent CTO recanalization by a high-volume operator were includ

225 Patients with unsuccessful CTO PCIs had significantly higher 2.5-year mortality (ad

226 l compared with procedures with unsuccessful CTO, and higher-volume CTO operators are more successful

227 tudy included 56 patients with single-vessel CTO and no prior MI who underwent rest-stress myocardial

228 In the setting of single-vessel CTO and no prior MI, coronary collaterals appear to prot

229 res with unsuccessful CTO, and higher-volume CTO operators are more successful.

230 We tested whether CTOs reduce admissions compared with use of Section 17 l

231 dergoing nonurgent coronary angiography with CTO were prospectively identified at 3 Canadian sites fr

232 success and low complications compared with CTO PCI in patients who never had CABG.

233 07), whereas fibrocalcific IP increased with CTO age (p = 0.008).

234 ssigned to control, and in all patients with CTO experience at any time in the 36 months versus those

235 fected readmission outcomes in patients with CTO experience.

236 ubgroup analysis revealed that patients with CTO located in the left anterior descending coronary art

237 Almost half the patients with CTO were treated medically, and 25% underwent coronary a

238 function was normal in >50% of patients with CTO.

239 ns without residual CTO-RCA (493 ULM without CTO-RCA+29 ULM with treated CTO-RCA), and 46 patients ha